Hubbry Logo
Diffuse alveolar damageDiffuse alveolar damageMain
Open search
Diffuse alveolar damage
Community hub
Diffuse alveolar damage
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Diffuse alveolar damage
Diffuse alveolar damage
Diffuse alveolar damage
View on Wikipedia
from Wikipedia
Diffuse alveolar damage
Micrograph showing hyaline membranes, the key histologic feature of diffuse alveolar damage. H&E stain.
SpecialtyRespirology

Diffuse alveolar damage (DAD) is a histologic term used to describe specific changes that occur to the structure of the lungs during injury or disease. Most often DAD is described in association with the early stages of acute respiratory distress syndrome (ARDS).[1] DAD can be seen in situations other than ARDS (such as acute interstitial pneumonia) and that ARDS can occur without DAD.[1]

Definitions

[edit]
  • Diffuse alveolar damage (DAD): an acute lung condition with the presence of hyaline membranes.[2] These hyaline membranes are made up of dead cells, surfactant, and proteins.[1] The hyaline membranes deposit along the walls of the alveoli, where gas exchange typically occurs, thereby making gas exchange difficult.
  • Acute respiratory distress syndrome (ARDS): a potentially life-threatening condition where the alveoli are damaged thereby letting fluid leak into the lungs which makes it difficult to exchange gases and oxygenate the blood.[3] It is the general practice of the medical community to use the Berlin criteria to diagnose ARDS. All criteria must be present to make a diagnosis of ARDS.

Berlin Criteria: as stated on UpToDate (2020)

[edit]

The Berlin Criteria specifies:[4]

  1. Timing: onset of respiratory symptoms within one week of an injury/insult.
  2. Chest Imaging: either chest x-ray or CT scan, must show bilateral opacities that cannot be fully explained by other conditions such as effusion, lung/lobar collapse, or lung nodules.
  3. Origin of Edema: respiratory failure that cannot be fully explained by cardiac failure or fluid overload, this needs objective assessment such as an echocardiogram.
  4. Impaired Oxygenation: this can be determined by looking at the ratio of arterial oxygen tension to fraction of inspired oxygen (PaO2/FiO2) that can be obtained based on an arterial blood gas test. Note: all PaO2/FiO2 ratios used in the determination of the severity of ARDS require that the patient be on a ventilator at a setting that includes 5 cm H2O or more of positive end-expiratory pressure (PEEP) or continuous positive airway pressure (CPAP).
Level of ARDS PaO2/FiO2 Range PEEP/CPAP
Mild ARDS 201–300 ≥5 cm H2O
Moderate ARDS 101–200
Severe ARDS <100

Histology/Progression

[edit]

The epithelial lining of alveoli are composed of two different types of cells. Alveolar type I epithelial cells comprise about 80% of the alveolar surface area and are primarily responsible for gas exchange.[5] Alveolar type II epithelial cells play the critical roles of producing surfactant, moving water out of the airspaces, and regenerating alveolar epithelium.[5] The alveolar type II epithelial cells are more resistant to damage, so after an insult to the alveoli, most of the damage will occur to the alveolar type I epithelial cells.[5]

Left side demonstrate the structure of a normal alveolus including the difference between type I and type II alveolar epithelial cells. Right side depicts what occurs after injury to the alveolus during the acute/exudative phase.

Once the initial insult has damaged the alveoli and begun the process of DAD, the condition will typically progress in three phases: exudative, proliferative, and fibrotic.[6] Below are the description of the phases, paraphrased from Sweeney et al. (2016).[6]

  • Exudative Phase (1–7 days): After the initial insult to the alveoli, immune cells (neutrophils and macrophages) are recruited to the alveoli, which can cause more damage through their nonspecific defensive mechanisms. Since the epithelial lining is damaged it allows plasma and proteins to leak in to the airspace, accumulating fluid (otherwise known as edema). Additionally, since the epithelial lining is damaged there is limited ability to pump this edema out of the airspace and back in to the interstitium. The presence of this edema has the following detrimental impacts:
    • The edema contributes to the deposition of a hyaline membrane (composed of dead cells, surfactant, and proteins) along the alveolar walls. Hyaline membranes are characteristic of DAD.
    • The edema interferes with the naturally occurring surfactant, which is critical for reducing surface tension and allowing alveoli to remain open and allow air in for gas exchange.
  • Proliferative/Organizing Phase (1–3 weeks): This phase is characterized by recovery. The epithelial lining is repopulated with alveolar type II epithelial cells which will eventually differentiate into alveolar type I epithelial cells. While the type II epithelial cells are repopulating the epithelial surface they are also performing the critical task of transporting the edema out of the airspace and back into the interstitium. Meanwhile, in the airspace, macrophages are clearing cellular debris.
  • Fibrotic Phase (after 3 weeks, if occurs): not all courses of DAD result in a fibrotic phase. This phase occurs if the alveolar collagen that is deposited during the acute exudative phase fails to be resorbed, resulting in limitations of alveolar expanse and subsequently gas exchange.

Causes/Mechanism

[edit]

DAD can occur in settings other than ARDS and that ARDS can occur with histology other than DAD. That being said, the histologic finding of DAD is often associated with the clinical syndrome ARDS but it can also be seen in conditions such as acute interstitial pneumonia (essentially ARDS but without a known inciting cause), acute exacerbation of idiopathic pulmonary fibrosis, and primary graft dysfunction after lung transplant.[1] The most common causes of ARDS are pneumonia, non-pulmonary sepsis, and aspiration.[7]

To reiterate, the hallmark of DAD is hyaline membrane formation.[1] There is a similar process which occurs in newborns called hyaline membrane disease, although the preferred term is surfactant-deficiency disorder, that also has the formation of hyaline membranes.[8] This disorder typically develops due to prematurity, especially when the infant is delivered prior to 36 weeks since surfactant doesn't start being produced until 35 weeks gestation.[8] The lack of surfactant causes alveolar collapse and subsequent damage to the epithelial lining of the alveoli, causing the same path of damage described in the above section.

Diagnosis

[edit]

In order to make a diagnosis of DAD a biopsy of the lung must be obtained, processed, and examined microscopically. As described above, the hallmark of diagnosing DAD is the presence of hyaline membranes.[1] Most frequently DAD is associated with ARDS, but since there are clinical criteria (see Berlin criteria above) upon which we can diagnose ARDS, it is often unnecessary in all cases to obtain invasive biopsies of the lung. Additionally, there are limitations of the biopsy test since it is possible to sample a potentially normal area of lung even though there is DAD in the rest of the lung, resulting in a false negative.[1]

Treatment

[edit]

The most important factor for treating DAD or ARDS is to treat the underlying cause of the injury to the lungs,[9] for example pneumonia or sepsis. These patients will have problems with oxygenation, meaning they will likely need a breathing tube, medications to keep them comfortable (sedative, paralytic, and/or analgesic), and a mechanical ventilator to breathe for them.[10] The mechanical ventilator will often be set to a setting of at least 5 cm H2O of positive end-expiratory pressure (PEEP) to keep the alveoli from collapsing during exhalation.[9] Other treatments to improve oxygenation may include prone positioning or extracorporeal membrane oxygenation (ECMO).[6]

Prognosis

[edit]

As expected, the mortality rates increase as the severity of the ARDS increases with mortality rates at approximately 35%, 40%, and 46% for mild, moderate, and severe, respectively.[11] It has been revealed that patients with ARDS that show DAD on histology are at a high mortality rate of 71.9% compared to 45.5% in patients with ARDS but without DAD.[12] Of the patients who succumb to ARDS, the most common cause of death is septic shock with multi organ dysfunction syndrome.[13]

Among survivors upon discharge, many will have impairments in their lung function. The majority (approximately 80%) of patient will have decrease diffusion capacity while fewer patients (approximately 20%) will have issues with airflow (either obstructive or restrictive).[14] These airflow issues will typically resolve within six months and the diffusion issues will resolve within five years.[14]

References

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Diffuse alveolar damage

View on Grokipedia
from Grokipedia
Diffuse alveolar damage (DAD) is the pathological hallmark of (ARDS), underlying approximately 40–60% of cases, with ARDS incidence ranging from 10 to 80 per 100,000 person-years. It is characterized by hyaline membrane formation, edema, , hemorrhage, and alveolar epithelial cell . This histological pattern manifests as a rapid and often fatal clinical course, typically presenting with deep that requires . DAD is the morphological prototype of acute interstitial pneumonia and is frequently identified in biopsies or autopsies of patients with severe acute . The of DAD evolves through distinct phases. The exudative phase, occurring within the first few days of , features intra-alveolar and , type I alveolar epithelial cell , and the development of membranes lining the alveoli, which typically appear 4–5 days post-damage. This is followed by the proliferative phase, marked by type II alveolar epithelial cell hyperplasia, organization of the into , and early fibrosis. In some cases, a fibrotic phase ensues, with extensive deposition and potential for persistent respiratory impairment. Delayed alveolar reepithelialization can occur, leading to atypical features such as alveolar denudation and bronchiolization, which may prolong recovery. Common etiologies of DAD include , shock, trauma, aspiration, and severe infections such as , though it can also arise idiopathically or as an exacerbation of underlying interstitial diseases. In ARDS patients undergoing open , DAD is present in approximately 56% of cases and is independently associated with increased mortality ( 3.554). Overall mortality rates for DAD have historically ranged from 43% to 50%, though recent ARDS mortality is reported at 25–45% as of 2025, underscoring its role as a critical determinant of outcomes in acute .

Introduction

Definition

Diffuse alveolar damage (DAD) is a nonspecific histological of acute lung characterized by damage to the alveolar epithelial and endothelial cells, resulting in protein-rich , formation of hyaline membranes lining the alveoli, and subsequent impairment of . This reflects a severe disruption of the alveolar-capillary barrier, leading to leakage of plasma proteins and fluids into the alveolar spaces. Although DAD serves as the microscopic correlate of clinical syndromes such as (ARDS) and acute interstitial pneumonia (AIP), it is not synonymous with them; ARDS represents a clinical based on acute hypoxemic with bilateral opacities, whereas DAD specifically denotes the underlying pathological findings confirmed by or . Similarly, AIP is an idiopathic form of acute histologically defined by organizing DAD in the absence of known causes. Key features of DAD include its bilateral and diffuse involvement of the lung alveoli, with a time-dependent progression from an initial exudative phase marked by and membranes to potential proliferative and fibrotic stages if the injury persists. The term "diffuse alveolar damage" was first introduced in 1976 by Katzenstein, Bloor, and Liebow to describe this pattern as the pathological hallmark of ARDS.

Epidemiology

Diffuse alveolar damage (DAD) is most commonly evaluated epidemiologically through its strong association with (ARDS), as DAD constitutes the predominant histological finding in approximately 50% of ARDS cases. The population incidence of ARDS, used as a proxy for DAD, ranges from 10 to 80 cases per 100,000 person-years, with U.S. estimates around 58 per 100,000 annually affecting over 190,000 individuals. In critical care settings, ARDS—and by extension DAD—occurs in 10-23% of admissions and up to 20% of mechanically ventilated patients. Direct registries for DAD are lacking, complicating precise prevalence data, though studies confirm its presence in the majority of fatal ARDS cases. Post-2020, the markedly elevated incidence, with DAD identified in approximately 80% of fatal severe cases via , contributing to a global surge in related acute lung injuries. Demographic patterns reveal higher DAD susceptibility among males, who comprise 60-70% of ARDS cases, and older adults over 65 years, where age-adjusted rates and mortality escalate progressively. Comorbidities such as , , , and further amplify risk, with these factors present in over 70% of affected patients. In contrast, pediatric incidence remains lower, estimated at 5-10 cases per 100,000 annually, with mortality rising but still below adult levels due to fewer comorbidities. Key risk factors for DAD include exposure to , which predisposes up to 20% of recipients to ARDS-like damage; , a common precipitant in 40-50% of cases. Global trends indicate a rising DAD burden post-2020, driven by pandemics like that peaked ARDS incidence at 20 per 100,000 in 2021, alongside aging populations where those over 65 face 23-fold higher risks.

Pathophysiology

Histological phases

Diffuse alveolar damage (DAD) progresses through distinct histological phases that reflect the temporal evolution of lung injury, typically observed in the context of (ARDS) or idiopathic acute interstitial pneumonia. These phases overlap and can vary based on the underlying insult, but they generally follow a sequence from acute injury to repair or . The exudative (acute) phase occurs within the first 1 to 7 days following injury and is characterized by widespread proteinaceous alveolar , formation of membranes lining the alveolar walls, of type I pneumocytes, congestion of pulmonary capillaries, and formation of microthrombi. These features result in diffuse involvement of the alveolar , with interstitial and intra-alveolar deposition and early inflammatory infiltrates, leading to impaired . membranes, composed of cellular debris and plasma proteins, are a hallmark finding and typically appear 4 to 5 days after onset. The proliferative (organizing) phase emerges around days 7 to 21, marking the transition to repair, with partial resolution of the initial and . Key features include of type II pneumocytes, which serve as progenitors for alveolar re-epithelialization, along with proliferation of fibroblasts and early deposition of in the alveolar septa and . This phase shows organization of the hyaline membranes into fibrotic foci and mild-to-moderate interstitial thickening, though the extent of resolution depends on the severity of the initial injury. In the fibrotic (chronic) phase, which develops beyond 21 days if the injury is unresolved, there is progression to intra-alveolar and interstitial , often with of the alveolar epithelium and potential changes resembling . This stage involves dense deposition, architectural distortion, and irreversible scarring, which can lead to chronic respiratory impairment. foci and intra-alveolar buds of are prominent, distinguishing it from earlier phases. Diagnosis of DAD histologically requires evidence of these phase-specific changes involving a widespread portion of the lung parenchyma, typically across multiple lobes, to qualify as "diffuse" rather than focal ; this overlaps with ARDS but can occur independently in conditions like acute interstitial pneumonia. Recent pathology reviews have reaffirmed the classic phase descriptions, though autopsy studies of cases indicate accelerated progression to proliferative or fibrotic stages in severe infections, with early fibrotic changes observed within weeks due to intense inflammatory responses.

Cellular and molecular mechanisms

Diffuse alveolar damage (DAD) begins with injury to the alveolar and , disrupting the alveolar-capillary barrier and increasing . This disruption allows protein-rich fluid, inflammatory cells, and mediators to flood the alveolar space, leading to formation. (ROS) generated by activated and endothelial cells contribute significantly to this damage by oxidizing cellular components, including proteins, which further compromises barrier integrity. Neutrophil activation, triggered by initial insults, amplifies the injury through the release of proteases and additional , perpetuating endothelial and epithelial . The inflammatory cascade in DAD involves a cytokine storm characterized by elevated levels of pro-inflammatory cytokines such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and interleukin-1β (IL-1β), which activate nuclear factor-kappa B (NF-κB) pathways in resident and recruited immune cells. This leads to massive influx of macrophages and neutrophils into the alveoli, where they release additional mediators that exacerbate tissue damage. Complement activation enhances this process by opsonizing pathogens and damaged cells, promoting further immune cell recruitment, while coagulation abnormalities, including disseminated intravascular coagulation, result from endothelial dysfunction and contribute to microvascular thrombosis within the lung. Surfactant dysfunction arises from the loss or injury of type II alveolar epithelial cells, which are responsible for producing —a lipid-protein complex that reduces and prevents alveolar collapse. Damage to these cells, often induced by ROS and cytokines, impairs surfactant synthesis and secretion, leading to increased alveolar , , and reduced . This dysfunction not only worsens but also promotes further mechanical stress on the remaining epithelial cells during ventilation. Repair failure in DAD is driven by dysregulated transforming growth factor-beta (TGF-β) signaling, which shifts the response from resolution toward excessive by activating fibroblasts and promoting deposition in the alveolar . Concurrently, excessive of alveolar epithelial cells, mediated by pro-apoptotic signals from cytokines and ROS, depletes the pool necessary for regeneration, preventing effective re-epithelialization. This imbalance results in the organizing phase of DAD, where fibroproliferative changes hinder lung recovery. Experimental models of DAD, such as those induced by endotoxin (, LPS) in , recapitulate the human histological phases through similar mechanisms of , , and barrier disruption. These models demonstrate how initial insults alter forces—specifically, by reducing gradients and increasing hydrostatic pressure across the damaged —leading to enhanced fluid and , providing insights into permeability dynamics without direct quantitative equations.

Etiology

Direct pulmonary insults

Direct pulmonary insults refer to injuries that primarily target the lung parenchyma, initiating diffuse alveolar damage (DAD) through local mechanisms such as epithelial disruption and inflammation. These insults account for approximately 50-60% of (ARDS) cases, the clinical correlate of DAD, with being the predominant etiology. Infectious causes represent a major subset of direct insults, comprising bacterial and viral pneumonias that directly invade alveolar and provoke cytokine-mediated damage. Viral pathogens such as and are well-documented triggers, with autopsy studies showing DAD in up to 88% of fatal cases and similar patterns in severe influenza infections. Aspiration pneumonitis, often from gastric contents, further contributes by introducing acidic and particulate matter that exacerbates alveolar injury. Collectively, infectious etiologies underlie about 60% of ARDS cases linked to direct lung injury. Toxic exposures directly impair alveolar integrity through chemical or physical mechanisms. Inhalation injuries from smoke, toxic gases, or fumes generate and thermal damage, leading to sloughing of type I pneumocytes and hyaline membrane formation characteristic of DAD. Radiation pneumonitis, resulting from thoracic radiotherapy, induces and superimposed on acute DAD. Near-drowning events cause similar via aspirated freshwater or saltwater, disrupting and promoting alveolar flooding. These insults are less common but often severe, with alone contributing to significant morbidity in fire victims. Traumatic direct insults include from blunt chest trauma, which mechanically disrupts alveolar walls and vasculature, and fat emboli syndrome following long-bone fractures, where lipid droplets occlude capillaries and trigger endothelial injury. These mechanisms culminate in the exudative phase of DAD, marked by protein-rich edema and early hyaline membranes. Iatrogenic insults arise in clinical settings, notably in mechanically ventilated patients, where prolonged high fractional inspired oxygen (FiO2 >60%) generates free radicals that damage type II pneumocytes and impair production. Post-lung , particularly primary graft dysfunction, manifests as with infiltration and DAD in up to 20-30% of recipients within the first 72 hours. Overall, direct insults are associated with biopsy-proven DAD in roughly 50% of cases, and some studies report higher mortality rates compared to indirect insults (e.g., 60% versus 40%), attributed to more focal and severe parenchymal involvement.

Indirect systemic insults

Indirect systemic insults encompass extrapulmonary conditions that precipitate diffuse alveolar damage (DAD) via widespread inflammatory and endothelial perturbations, rather than primary lung targeting. These insults often initiate with vascular endothelial injury, leading to heightened permeability, protein-rich , and subsequent alveolar flooding, with comparatively less immediate epithelial disruption than seen in direct insults. Early resolution of the underlying systemic trigger can promote reversibility by mitigating ongoing inflammation and permitting endothelial repair. Sepsis and shock, typically arising from extrapulmonary infections like intra-abdominal sources, represent the predominant indirect of DAD, comprising roughly 40% of associated (ARDS) cases. These states unleash a proinflammatory —elevated levels of tumor necrosis factor-alpha and interleukin-6—that propagates to the pulmonary vasculature, eroding the alveolar-capillary barrier through activation and . Noninfectious shock, such as hypovolemic or cardiogenic forms, similarly amplifies this systemic response, exacerbating and capillary leak. Multiple trauma and severe burns constitute another key category of indirect insults, where massive tissue destruction unleashes systemic inflammatory mediators that secondarily assail the lungs. In trauma, factors like fat emboli and hypoperfusion compound the release of damage-associated molecular patterns, fostering endothelial activation and abnormalities that culminate in DAD. Burns, particularly those exceeding 30% total , elicit a hypermetabolic state with elevated circulating cytokines, mirroring sepsis-induced pathways and increasing DAD risk through remote organ . Additional indirect triggers include , massive blood transfusions, , and certain drug toxicities. Pancreatitis provokes DAD via trypsin-mediated complement activation and cytokine release, leading to sequestration in the s and vascular . Transfusion-related acute from massive volumes (>10 units) involves donor antibodies and bioactive that incite endothelial and priming. during heightens DAD incidence through ischemia-reperfusion and inflammatory priming, with histopathological evidence of hyaline membranes in up to 69% of cases. Drug toxicities, notably from and chemotherapeutic agents like , induce DAD through phospholipidosis or oxidative epithelial stress, manifesting as organizing or acute patterns. In , DAD emerges as a complication in 2-14% of recipients, driven by conditioning regimen toxicity, , and opportunistic infections that amplify systemic inflammation. These insults often activate overlapping inflammatory pathways, such as nuclear factor-kappa B signaling, detailed elsewhere in cellular mechanisms.

Diagnosis

Clinical criteria for associated syndromes

Diffuse alveolar damage (DAD) serves as the histopathological hallmark of the (ARDS), a clinical syndrome characterized by acute hypoxemic . The Berlin Definition, established in 2012, provides the foundational clinical criteria for ARDS diagnosis, requiring acute onset within one week of a known clinical or new/worsening respiratory symptoms, bilateral opacities on chest imaging not fully explained by effusions, lobar/ collapse, or nodules, not fully explained by cardiac failure or fluid overload (with objective assessment such as needed to exclude hydrostatic if no is present), and a PaO₂/FiO₂ ratio of ≤300 mmHg with a minimum (PEEP) of 5 cmH₂O. Severity is stratified into mild (PaO₂/FiO₂ 200-300 mmHg with PEEP ≥5 cmH₂O), moderate (100-200 mmHg with PEEP ≥5 cmH₂O), and severe (<100 mmHg with PEEP ≥5 cmH₂O) categories, which correlate with increasing mortality risks of approximately 27%, 32%, and 45%, respectively. Acute interstitial pneumonia (AIP), also known as Hamman-Rich syndrome, represents the idiopathic form of and is diagnosed clinically by rapid progression to severe hypoxemia and respiratory failure over days to weeks in the absence of identifiable causes such as infection, toxins, or systemic insults. Diagnostic criteria for AIP emphasize its acute onset (typically <1 month), diffuse bilateral infiltrates on imaging, severe hypoxemia (PaO₂/FiO₂ ≤300 mmHg), and exclusion of alternative etiologies through comprehensive evaluation, including bronchoalveolar lavage to rule out infection and serological tests for connective tissue diseases. Unlike , AIP lacks an antecedent trigger and progresses to end-stage fibrosis if untreated, with mortality exceeding 50% in the acute phase. To differentiate DAD-related syndromes from hydrostatic (cardiogenic) pulmonary , clinical evaluation incorporates objective measures such as echocardiography to assess left ventricular function and pulmonary artery wedge pressure, or B-type natriuretic peptide (BNP) levels, though BNP has limited specificity in critically ill patients and is best used adjunctively. Elevated BNP (>100 pg/mL) or echocardiographic evidence of systolic/diastolic dysfunction supports hydrostatic , prompting exclusion from ARDS criteria. The 2023 European Society of Intensive Care Medicine (ESICM) guidelines refine ARDS diagnostic and phenotyping approaches, incorporating subphenotypes based on inflammatory biomarkers (e.g., IL-6, IL-8) and radiographic patterns to enhance precision in heterogeneous populations, while maintaining core elements. These updates address limitations in earlier frameworks, particularly for COVID-19-associated ARDS, where onset often exceeds one week (8-12 days) and may be preserved despite severe , necessitating flexible application of timing criteria without altering oxygenation thresholds. Building further on these, the 2023 Global Definition of ARDS, proposed by an international expert panel, enhances inclusivity by applying to both intubated and non-intubated patients and resource-variable settings. It retains the 1-week timing, bilateral opacities not fully explained by other causes, and non-cardiogenic origin but expands oxygenation assessment to include SpO₂:FiO₂ ≤315 (if SpO₂ ≤97%) on high-flow nasal oxygen (≥30 L/min) or /CPAP (≥5 cm H₂O PEEP). In resource-limited contexts, PEEP and specific device requirements are waived. Severity remains mild (PaO₂:FiO₂ >200 or SpO₂:FiO₂ >235), moderate (100-200 or 148-235), and severe (≤100 or ≤148), with ongoing validation as of 2025.

Imaging features

On chest X-ray, diffuse alveolar damage (DAD) typically presents with bilateral diffuse opacities and air-space consolidation that often initially spares the costophrenic angles, reflecting the early exudative phase of acute lung injury. These findings usually emerge 12-24 hours after the inciting insult and rapidly progress to confluent, patchy alveolar infiltrates involving multiple lobes, sometimes resulting in a "white lung" appearance in severe cases. High-resolution computed tomography (CT) is more sensitive for early detection and reveals characteristic patterns including ground-glass opacities, consolidation, and interlobular septal thickening, often with a "crazy-paving" appearance due to superimposed smooth septal lines. In the acute phase, dependent predominates in dorsal regions, while the chronic or organizing phase shows traction , reticular opacities, and , particularly in anterior lung zones due to ventilator-induced injury. Disease progression on CT evolves from early diffuse alveolar filling with ground-glass opacities and consolidation to later reticular changes and architectural distortion; in COVID-19-associated DAD, peripheral "crazy-paving" patterns are notably common. Although CT demonstrates greater sensitivity than chest for early DAD detection (with sensitivity around 73%), imaging alone is not diagnostic and cannot reliably distinguish DAD from other pneumonias without clinical correlation. In the context of (ARDS), which encompasses DAD, histological confirmation correlates with findings, though this requires histopathological evaluation for definitive . Limitations include the nonspecific nature of these patterns and risks associated with patient transport for CT in critically ill individuals.

Histopathological findings

The histopathological diagnosis of diffuse alveolar damage (DAD) relies on or specimens, as it provides definitive microscopic evidence of the injury pattern underlying (ARDS). Transbronchial has limited utility due to small sample size and potential sampling errors in patchy disease, often failing to capture the full extent of involvement. Surgical or open serves as the gold standard for antemortem confirmation but is rarely performed owing to procedural risks, including , bleeding, and hemodynamic instability in critically ill patients. examinations are more commonly used for postmortem verification, allowing comprehensive sampling across multiple lung lobes to assess the diffuse nature of the damage. Key microscopic features of DAD include membranes lining alveolar ducts and spaces, which are composed of cellular debris, plasma proteins, and ; these membranes are periodic acid-Schiff ()-positive and represent the exudative phase of injury. Additional findings encompass alveolar septal , congestion, and early type II pneumocyte hyperplasia, with the damage requiring widespread involvement—typically affecting more than three alveoli per across multiple lobes—to meet criteria for diffuseness. These features must be temporally uniform without significant chronic changes to distinguish acute DAD from other patterns. Differential diagnosis on biopsy involves distinguishing DAD from organizing pneumonia, which lacks hyaline membranes and instead shows intra-alveolar fibroblastic plugs; diffuse alveolar hemorrhage, characterized by predominant accumulation and hemosiderin-laden macrophages without prominent hyaline material; and (UIP), which features temporal heterogeneity with , , and absence of acute exudative elements like hyaline membranes. Sampling pitfalls, such as focal involvement or inadequate tissue procurement, can lead to false negatives due to the heterogeneous distribution of lesions, underscoring the need for multiple-site sampling. The presence of DAD on open lung biopsy is associated with significantly higher mortality in ARDS patients, with rates approaching 71-72% compared to 45% in those without histologic DAD, independent of clinical severity. Recent pathology reviews highlight the underutilization of biopsies in clinical practice, attributing this to risks and the sufficiency of clinical criteria for most diagnoses, though they advocate for a multidisciplinary approach involving pathologists, clinicians, and radiologists to integrate biopsy findings when performed.

Management

Supportive care

Supportive care for diffuse alveolar damage (DAD), the underlying pathology of (ARDS), focuses on maintaining organ and while minimizing further . Mechanical remains the cornerstone, employing a -protective strategy to reduce ventilator-induced . This involves using low tidal volumes of 6 mL/kg of predicted body weight, with plateau pressures maintained below 30 cmH₂O, as established by the ARDS Clinical Trials Network (ARDSNet) protocol. (PEEP) is titrated to optimize oxygenation while avoiding , typically targeting a of arterial oxygen (PaO₂) of 55-80 mmHg or (SpO₂) of 88-95%. This approach has been shown to decrease mortality by approximately 9% compared to traditional higher tidal volumes. The 2023 American Thoracic Society (ATS) and European Society of (ESICM) guidelines reaffirm these parameters as standard for all ARDS patients, including those with DAD. For patients with severe ARDS (PaO₂/FiO₂ ≤150 mmHg), prone positioning for at least 12-16 hours daily is recommended to improve ventilation-perfusion matching and reduce mortality. The Prone Positioning in Severe (PROSEVA) trial demonstrated a 16% absolute reduction in 28-day mortality (from 32.8% in the supine group to 16% in the prone group) when initiated early after stabilization. This intervention is particularly beneficial in DAD-related ARDS, where alveolar collapse contributes to refractory , and is endorsed by the 2023 ATS/ESICM guidelines for moderate-to-severe cases. In early severe ARDS (within 48 hours of onset, PaO₂/FiO₂ ≤150 mmHg), continuous neuromuscular blocking agents (e.g., cisatracurium infusion) for up to 48 hours may be considered to optimize lung-protective ventilation, improve oxygenation, and potentially reduce mortality, as conditionally recommended by the 2023 ATS/ESICM guidelines. Fluid management adopts a conservative post-initial to limit , targeting a (CVP) of ≤4 mmHg or pulmonary artery occlusion pressure (PAOP) of ≤8 mmHg, with avoidance of excessive crystalloid administration. The Fluids and Catheters Treatment Trial (FACTT) showed that this approach shortens mechanical ventilation duration by two days and reduces stay without increasing shock risk. In DAD, where capillary leak exacerbates alveolar flooding, conservative fluid balance helps preserve . Nutritional support emphasizes early enteral feeding, initiated within 24-48 hours of ICU admission, to maintain gut barrier function and reduce infectious complications. Guidelines from the Society of Critical Care Medicine (SCCM) and ASPEN recommend trophic feeds (10-20 kcal/hour) initially, advancing to goal calories (25-30 kcal/kg/day) as tolerated, preferring enteral over parenteral routes in ARDS patients. Sedation practices prioritize minimal dosing with non-benzodiazepine agents (e.g., or ) to facilitate patient interaction and prevent , which affects up to 80% of mechanically ventilated ARDS patients. The 2018 SCCM , Agitation/sedation, , Immobility, and Disruption (PADIS) guidelines advocate for analgesia-first protocols and daily sedation interruptions to lower incidence and improve outcomes. Ongoing monitoring includes daily assessments for readiness, using spontaneous breathing s (e.g., pressure support ≤5 cmH₂O or T-piece for 30-120 minutes) once criteria like PaO₂/FiO₂ >150 and hemodynamic stability are met. For refractory despite optimized ventilation, (ECMO) serves as rescue therapy in select cases, utilized in fewer than 5% of ARDS patients overall. The ECMO to Initiate Oxygenation and Function (EOLIA) supports its use in severe DAD-related ARDS (PaO₂/FiO₂ <80 mmHg for >6 hours), showing a trend toward reduced 60-day mortality (35% vs. 46%) without significant harm. The ARDSNet protocol's principles, including these supportive elements, continue to form the evidence base for DAD management, with reductions in ventilator-induced injury confirmed in contemporary guidelines.

Targeted therapies

Targeted therapies for diffuse alveolar damage (DAD) focus on addressing underlying etiologies or specific pathophysiological pathways, such as , , or , while supportive care manages . In cases of infectious etiology, such as or leading to DAD, broad-spectrum antibiotics are initiated empirically to cover common pathogens, with de-escalation based on results and clinical response. For viral causes, including COVID-19-associated DAD, is administered to inhibit , demonstrating accelerated recovery in hospitalized patients with lower respiratory tract disease. Anti-inflammatory agents, particularly corticosteroids, target excessive immune responses in non-infectious DAD. The 2023 American Thoracic Society (ATS) clinical practice guideline conditionally recommends corticosteroids for moderate-to-severe ARDS, reporting a in mortality of 0.84 (95% CI 0.73–0.96) and shortened duration by approximately 4 days. In idiopathic forms like acute interstitial pneumonia (AIP), high-dose pulse (e.g., 500–1000 mg/day for 3 days) followed by a taper is commonly used, with case series indicating potential improvements in oxygenation and survival, though randomized evidence remains limited. Routine use is not advised for all ARDS cases per the 2024 Society of Critical Care Medicine (SCCM) guidelines, emphasizing initiation within 72 hours for moderate-to-severe presentations to mitigate risks like . Additional targeted interventions include for immune-mediated DAD, such as in transplant recipients, where high-dose corticosteroids form the cornerstone, often augmented by agents like to suppress ongoing alveolar injury. For microvascular contributing to DAD, anticoagulants like are considered in select patients without contraindications, as preclinical and observational data suggest benefits in reducing deposition and inflammation, though routine therapeutic anticoagulation is not guideline-recommended, while standard VTE prophylaxis is advised. Emerging therapies aim at alveolar repair and modulation of dysregulated pathways. (MSC) infusions, evaluated in phase II trials, promote lung repair by reducing inflammation and endothelial permeability, with 2024 meta-analyses of over 200 patients showing modest mortality reductions (risk ratio 0.88, 95% CI 0.64–1.21) and improved PaO₂/FiO₂ ratios, particularly when administered early. Phase III trials are ongoing, but no disease-modifying agents for DAD are currently approved. Recent 2023–2025 reviews underscore personalized strategies based on ARDS subphenotypes, distinguishing hyperinflammatory (elevated IL-6, IL-8) from hypoinflammatory profiles, with the former benefiting more from corticosteroids or IL-1 antagonists like , while the latter may require alternative immunomodulation to optimize outcomes.

Prognosis

Short-term outcomes

Diffuse alveolar damage (DAD), the histological hallmark of (ARDS), is associated with high short-term mortality, ranging from 40% to 60% overall in affected patients. In severe ARDS cases, mortality reaches approximately 46%, while biopsy-proven DAD elevates this risk to about 71%, reflecting the severity of alveolar injury and associated systemic complications. The majority of deaths occur within the first 28 days, primarily driven by multi-organ failure rather than isolated respiratory collapse. Key risk factors for short-term mortality include progression to the fibrotic phase of DAD, which signals unresolved injury and correlates with poorer outcomes; as a precipitant or complication; and advanced age over 65 years, which independently heightens vulnerability due to reduced physiological reserve. Infections cause approximately 22% of DAD cases, often exacerbating the exudative and proliferative phases through secondary . Common short-term complications include , occurring in 20-30% of mechanically ventilated ARDS patients with DAD, which prolongs intensive care stays and worsens oxygenation. , manifesting as , affects about 10% of cases, particularly in those requiring high ventilatory pressures, and can precipitate acute . Positive predictors of short-term survival encompass early resolution of the exudative phase on imaging or clinical assessment, indicating effective alveolar repair, and early improvement in the PaO₂/FiO₂ ratio within 48 hours of onset, which signifies responsive and lower risk of progression. Recent 2024 studies on COVID-19-associated DAD report mortality rates around 50% in severe cases.

Long-term complications

Survivors of diffuse alveolar damage (DAD), the histological hallmark of (ARDS), often face persistent pulmonary sequelae that impair long-term respiratory function. Approximately 20-30% of survivors develop , manifesting as restrictive lung physiology with reduced lung volumes and compliance. This contributes to chronic dyspnea, which persists in many patients for 6-12 months post-discharge, alongside a significant reduction in (DLCO), often averaging 65% of predicted values at one year. Beyond pulmonary effects, systemic complications are prevalent, encompassing elements of (PICS) that affect up to 50% of ARDS survivors. Cognitive impairments, including memory deficits and , occur in about 25-50% of cases, while leads to reduced exercise capacity and in a similar proportion. Psychological sequelae, such as (PTSD), affect 23-38% of survivors, often linked to ICU-related traumatic memories and contributing to diminished . The recovery timeline varies, with lung function improving substantially in approximately 80% of non-fibrotic cases by , though full resolution may take up to five years in some cases. risk is elevated in the organizing phase of DAD, where deposition predominates. programs have demonstrated efficacy in enhancing functional outcomes, with early intervention accelerating exercise capacity and reducing dyspnea. Guidelines, including the American Thoracic Society's 2023 clinical practice guideline on , advocate for routine screening and multidisciplinary rehabilitation to mitigate these complications. Despite these insights, long-term data specific to DAD remain limited, with most evidence derived from broader ARDS cohorts; as of 2025, ongoing studies emphasize higher risk in DAD-confirmed cases. Post-COVID-19 ARDS studies highlight prolonged in about 40-50% of survivors, underscoring ongoing needs for targeted interventions.

References

  1. https://www.pathologyoutlines.com/topic/lungnontumordiffusealveolardamage.html
  2. https://pmc.ncbi.nlm.nih.gov/articles/PMC4449559/
  3. https://pmc.ncbi.nlm.nih.gov/articles/PMC3458269/
  4. https://pmc.ncbi.nlm.nih.gov/articles/PMC5821904/
  5. https://www.sciencedirect.com/science/article/pii/S0954611120303796
  6. https://pubmed.ncbi.nlm.nih.gov/40548741/
  7. https://www.atsjournals.org/doi/10.1513/AnnalsATS.201609-728PS
  8. https://radiopaedia.org/articles/diffuse-alveolar-damage?lang=us
  9. https://www.merckmanuals.com/professional/pulmonary-disorders/interstitial-lung-diseases/acute-interstitial-pneumonia-aip
  10. https://www.sciencedirect.com/topics/medicine-and-dentistry/diffuse-alveolar-damage
  11. https://pmc.ncbi.nlm.nih.gov/articles/PMC2032554/
  12. https://www.medintensiva.org/en-acute-respiratory-distress-from-syndrome-articulo-S2173572716000187
  13. https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2021.750568/full
  14. https://atm.amegroups.org/article/view/15694/15774
  15. https://pmc.ncbi.nlm.nih.gov/articles/PMC7870331/
  16. https://pmc.ncbi.nlm.nih.gov/articles/PMC10644454/
  17. https://pmc.ncbi.nlm.nih.gov/articles/PMC8132567/
  18. https://jtd.amegroups.org/article/view/12630/html
  19. https://jintensivecare.biomedcentral.com/articles/10.1186/s40560-025-00781-3
  20. https://pmc.ncbi.nlm.nih.gov/articles/PMC6476679/
  21. https://www.mayoclinic.org/diseases-conditions/ards/symptoms-causes/syc-20355576
  22. https://www.aging-us.com/article/103344/text
  23. https://pmc.ncbi.nlm.nih.gov/articles/PMC8161799/
  24. https://pubmed.ncbi.nlm.nih.gov/28570160/
  25. https://pmc.ncbi.nlm.nih.gov/articles/PMC7152358/
  26. https://pmc.ncbi.nlm.nih.gov/articles/PMC7315337/
  27. https://doi.org/10.1038/s41379-020-00661-1
  28. https://pmc.ncbi.nlm.nih.gov/articles/PMC8848295/
  29. https://pmc.ncbi.nlm.nih.gov/articles/PMC11827456/
  30. https://molmed.biomedcentral.com/articles/10.2119/molmed.2010.00138
  31. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1603287/full
  32. https://www.nature.com/articles/s41392-025-02127-9
  33. https://pmc.ncbi.nlm.nih.gov/articles/PMC11524396/
  34. https://respiratory-research.biomedcentral.com/articles/10.1186/rr86
  35. https://pmc.ncbi.nlm.nih.gov/articles/PMC7256165/
  36. https://journals.sagepub.com/doi/pdf/10.1177/1753465810379801
  37. https://pmc.ncbi.nlm.nih.gov/articles/PMC8056939/
  38. https://www.aafp.org/pubs/afp/issues/2020/0615/p730.html
  39. https://pmc.ncbi.nlm.nih.gov/articles/PMC4254695/
  40. https://www.nature.com/articles/s41579-021-00542-7
  41. https://journal.chestnet.org/article/S0012-3692%2820%2934868-6/abstract
  42. https://thoracickey.com/diffuse-alveolar-damage-2/
  43. https://www.ncbi.nlm.nih.gov/books/NBK513261/
  44. https://www.ncbi.nlm.nih.gov/books/NBK564391/
  45. https://www.jhltonline.org/article/S1053-2498%2812%2900015-0/fulltext
  46. https://pmc.ncbi.nlm.nih.gov/articles/PMC9697068/
  47. https://med.stanford.edu/content/dam/sm/criticalcare/documents/ARDS_Review.pdf
  48. https://pmc.ncbi.nlm.nih.gov/articles/PMC7199454/
  49. https://ecommons.aku.edu/cgi/viewcontent.cgi?article=1098&context=pakistan_fhs_mc_anaesth
  50. https://pmc.ncbi.nlm.nih.gov/articles/PMC5266233/
  51. https://pmc.ncbi.nlm.nih.gov/articles/PMC5793936/
  52. https://pubmed.ncbi.nlm.nih.gov/9605066/
  53. https://pmc.ncbi.nlm.nih.gov/articles/PMC6827782/
  54. https://accpjournals.onlinelibrary.wiley.com/doi/abs/10.1002/phar.2630
  55. https://jamanetwork.com/journals/jama/fullarticle/1160659
  56. https://pubmed.ncbi.nlm.nih.gov/23001802/
  57. https://www.ncbi.nlm.nih.gov/books/NBK554429/
  58. https://www.dynamed.com/condition/acute-respiratory-distress-syndrome-ards-in-adults
  59. https://pmc.ncbi.nlm.nih.gov/articles/PMC2374600/
  60. https://link.springer.com/article/10.1007/s00134-023-07050-7
  61. https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-02911-9
  62. https://www.atsjournals.org/doi/10.1164/rccm.202303-0558WS
  63. https://accessmedicine.mhmedical.com/content.aspx?sectionid=279903288&bookid=3343
  64. https://pmc.ncbi.nlm.nih.gov/articles/PMC8286037/
  65. https://pubs.rsna.org/doi/full/10.1148/rg.220176
  66. https://pmc.ncbi.nlm.nih.gov/articles/PMC9487404/
  67. https://pubmed.ncbi.nlm.nih.gov/21428112/
  68. https://pmc.ncbi.nlm.nih.gov/articles/PMC5632979/
  69. https://www.annclinlabsci.org/content/11/1/25.full.pdf
  70. https://www.nature.com/articles/s41467-020-20139-7
  71. https://meridian.allenpress.com/aplm/article/141/7/916/65737/Pulmonary-Manifestations-of-Acute-Lung-Injury-More
  72. https://pmc.ncbi.nlm.nih.gov/articles/PMC3651925/
  73. https://pubmed.ncbi.nlm.nih.gov/26896701/
  74. https://www.nejm.org/doi/full/10.1056/NEJM200005043421801
  75. https://www.nejm.org/doi/full/10.1056/NEJMoa032193
  76. https://www.atsjournals.org/doi/10.1164/rccm.202311-2011ST
  77. https://pmc.ncbi.nlm.nih.gov/articles/PMC10354163/
  78. https://www.nejm.org/doi/full/10.1056/NEJMoa1214103
  79. https://www.nejm.org/doi/full/10.1056/NEJMoa062200
  80. https://pmc.ncbi.nlm.nih.gov/articles/PMC6546102/
  81. https://journals.lww.com/ccmjournal/Fulltext/2016/02000/Guidelines_for_the_Provision_and_Assessment_of.25.aspx
  82. https://annalsofintensivecare.springeropen.com/articles/10.1186/s13613-025-01509-0
  83. https://journals.lww.com/ccmjournal/fulltext/2018/09000/clinical_practice_guidelines_for_the_prevention.29.aspx
  84. https://pmc.ncbi.nlm.nih.gov/articles/PMC7653978/
  85. https://www.ncbi.nlm.nih.gov/books/NBK430712/
  86. https://www.nejm.org/doi/full/10.1056/NEJMoa1800385
  87. https://annalsofintensivecare.springeropen.com/articles/10.1186/s13613-021-00897-3
  88. https://pubmed.ncbi.nlm.nih.gov/37112927/
  89. https://pubmed.ncbi.nlm.nih.gov/38240492/
  90. https://accpjournals.onlinelibrary.wiley.com/doi/10.1002/phar.2630
  91. https://pmc.ncbi.nlm.nih.gov/articles/PMC5799142/
  92. https://pmc.ncbi.nlm.nih.gov/articles/PMC12465782/
  93. https://stemcellres.biomedcentral.com/articles/10.1186/s13287-025-04614-w
  94. https://pmc.ncbi.nlm.nih.gov/articles/PMC6709677/
  95. https://www.ncbi.nlm.nih.gov/books/NBK436002/
  96. https://pubmed.ncbi.nlm.nih.gov/21157315/
  97. https://publications.ersnet.org/content/erj/43/1/276
  98. https://pmc.ncbi.nlm.nih.gov/articles/PMC7649269/
  99. https://onlinelibrary.wiley.com/doi/10.1155/2011/531302
  100. https://www.atsjournals.org/doi/full/10.1164/ajrccm.161.6.9909122
  101. https://www.ijcasereportsandimages.com/archive/print/101191Z01KL2021
  102. https://pmc.ncbi.nlm.nih.gov/articles/PMC7343354/
  103. https://advances.massgeneral.org/research-and-innovation/article.aspx?id=1238
  104. https://respiratory-research.biomedcentral.com/articles/10.1186/s12931-021-01625-y
  105. https://www.ncbi.nlm.nih.gov/books/NBK558964/
  106. https://www.atsjournals.org/doi/10.1164/rccm.202009-3381OC
  107. https://www.esicm.org/article-review-icm-ptsd-psychiatric-symptoms-after-ards/
  108. https://www.thoracic.org/statements/guideline-implementation-tools/matrix-guidelines-and-derivatives-pulmonary-rehab-in-adults-08-23-23.php
  109. https://www.atsjournals.org/doi/10.1513/AnnalsATS.202009-1175OC
  110. https://journals.lww.com/ccejournal/fulltext/2025/07000/long_term_cardiopulmonary_function_after.6.aspx
Add your contribution
Related Hubs
User Avatar
No comments yet.